Early intraperitoneal chemotherapy (EIPC) is administered directly into the abdominal cavity. The first dose of chemolytic agents may be infused post-surgery with subsequent doses given over a course of several days.
Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC), also referred to as intraperitoneal hyperthermic chemotherapy (IPHC), is instilled during surgery, via an open or closed abdominal approach. The heated chemolytic agent is infused into the peritoneal cavity, raising the temperature of the tissues within the cavity to 106–108 °Fahrenheit (F). Because various tissue thicknesses are present within the peritoneal cavity, there is a concern that the entire cavity may not be receiving an even exposure to the medication. Extensive surgical debulking is imperative.
Early Intraperitoneal chemotherapy (EPIC) or Hyperthermic intraoperative Intraperitoneal chemotherapy (HIPEC) may be considered medically necessary when used in combination with cytoreductive surgery for ANY ONE of the following indications:
EPIC or HIPEC reported for any other indication is considered experimental/investigational, and therefore, non-covered. Scientific evidence does not support the use of EPIC and HIPEC for any other indications.